Oral dydrogesterone treatment during early pregnancy to prevent recurrent pregnancy loss and its role in modulation of cytokine production: a double-blind, randomized, parallel, placebo-controlled trial Ashok Kumar, M.D., Ph.D., Nargis Begum, M.Sc., Ph.D., Sudha Prasad, M.D., Sarita Aggarwal, M.D., Shashi Sharma, Ph.D. Fertility and Sterility Volume 102, Issue 5, Pages 1357-1363.e3 (November 2014) DOI: 10.1016/j.fertnstert.2014.07.1251 Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions
Figure 1 Trial profile showing representative numbers of women in the study. Fertility and Sterility 2014 102, 1357-1363.e3DOI: (10.1016/j.fertnstert.2014.07.1251) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 1 Cytokine profile of controls and RPL group. Fertility and Sterility 2014 102, 1357-1363.e3DOI: (10.1016/j.fertnstert.2014.07.1251) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 2 Percentage change of cytokines (mean ± standard error) in women who had a miscarriage and women who continued the pregnancy beyond 20 weeks of gestation. (A) A statistically significant percentage change of IL-10 level was observed between [1] controls and the placebo group, and [2] controls and the dydrogesterone group. (B) A statistically significant percentage change of IL-4 level was observed between controls and the placebo group. A statistically significant percentage change of IL-10 level was observed between the placebo group and the dydrogesterone group. A statistically significant percentage change of IFN-γ level was observed between [1] controls and the placebo group, and [2] controls and the dydrogesterone group. Fertility and Sterility 2014 102, 1357-1363.e3DOI: (10.1016/j.fertnstert.2014.07.1251) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions
Supplemental Figure 3 Serum cytokine levels (mean ± standard error) at recruitment in the study group with respect to adverse pregnancy outcomes. (A) Serum IL-4 level was significantly higher in preterm delivery and LBW babies in the healthy pregnant control group. (B) Serum IL-10 level was comparable for adverse pregnancy outcomes among the study groups. (C) Serum TNF-α level was significantly higher in preterm delivery in the healthy pregnant control group. (D) Serum IFN-γ was significantly lower in preterm delivery and SFD babies in the placebo group; it was significantly higher in LBW babies in the dydrogesterone group. AFD = appropriate for date; LBW = low birth weight; SFD = small for date. Fertility and Sterility 2014 102, 1357-1363.e3DOI: (10.1016/j.fertnstert.2014.07.1251) Copyright © 2014 American Society for Reproductive Medicine Terms and Conditions